• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Spark Therapeutics Appoints CTO

    Cryoport Launches ESG Program

    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail

    Thermo Fisher Scientific Completes Mesa Biotech Acquisition

    Ashfield Engage, Popit Form Digital Monitoring Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Solid Dose Market Trends

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Reed-Lane

    Baxter BioPharma Solutions

    test company saurabh

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Emergent BioSolutions

    Baxter BioPharma Solutions

    Alcami

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    FDA Watch

    The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

    Some tips to make your trip along the regulatory pathway to report manufacturing changes easier.

    The Art of Filing NDA/ANDA Post-Approval Changes to the FDA
    Amy Schutte, Senior Associate, Lachman Consultant Services03.04.20
    Change is inevitable, continuous, and reportable to the FDA when we are talking about approved human or animal drugs. Specifically, this article seeks to discuss some of the challenges caused by changes, and some thoughts on reporting changes, for branded or generic drugs approved for human use under a New Drug Applications (NDA) or Abbreviated New Drug Applications (ANDA), respectively.

    Recently at a conference sponsored by the Association of Affordable Medicines (AAM), speakers from FDA’s Office of Generic Drugs presented that the top two categories of post-approval supplements submitted for ANDAs were related to manufacturing site and manufacturing process; the next three categories of change were also related to manufacturing (i.e., changes to specifications, testing, container/closure, and composition).1 It is not a far stretch to assume that manufacturing changes similarly represent a large portion of the supplements received by the Office of New Drugs. In fact, the first two sections of FDA’s Guidance, Changes to an Approved NDA or ANDA,2 address manufacturing changes and how to report them and more recently FDA’s Draft Guidance, Post-approval Changes to Drug Substances,3 also makes significant reference to manufacturing change, so it seems to be a subject of particular importance.

    Unfortunately, even the simplest changes can face hurdles. The requirements for some annual reportable changes, such as Residual Solvents compliance with USP <467> and Elemental Impurities compliance with USP <232>, were found to be a challenge for organizations to assess. When big changes come up in a manufacturing organization, having a regulatory resource present to give an initial assessment of how the change may be handled, and what work might be needed to support the eventual filing to the FDA, is important. A little planning can go a long way—supplements that are needed immediately because they impact product release or are gating to production are not an ideal situation for any company to be in. A robust change management system with a required regulatory assessment can often head this off, but an upfront discussion with the Regulatory Department never hurts when change is brewing in a facility.

    More importantly, if left out of the conversation, Regulatory may miss the opportunity to devise a more creative post-approval regulatory pathway than can be managed when there is pressure to submit immediately. Outside of combing through the relevant Change Guidances,2,3,4 Scale-Up and Post-approval Changes (SUPAC) Guidances,5,6,7 and prior change precedents to see if the specific manufacturing change fits into any obvious category, there are several forward-looking regulatory pathways that can be used to help facilitate and implement significant changes that can have an impact on patient supply. This article considers a few of these options in relation to examples that may occur in a manufacturing facility.

    Comparability protocols
    If a change is identified well in advance, the use of a comparability protocol may be something to consider. The FDA issued a Draft Guidance, Comparability Protocols for Human Drugs and Biologics: Chemistry, Manufacturing, and Controls Information, on April 20168 which describes the potential application and use of comparability protocols. This might be a regulatory pathway to consider for changes such as future product manufacturing scale-up, equipment changes, specification changes, or container/closure changes. Comparability protocols must be approved by the FDA in advance of the proposed change and may be submitted in either the original NDA or ANDA or after approval via prior-approval supplement. They can be used to facilitate a one-time change or a re-occurring change throughout the product’s lifecycle.

    For this to be a viable regulatory pathway for an anticipated future change, sufficient information and data to support the change—any specific studies, risk assessment, control strategy, side-by-side specification comparison, etc.—will need to be available for the FDA’s consideration. One additional benefit of the comparability protocol is that a reduced reporting category may be proposed, such as a Changes Being Effected (CBE) supplement or even via an Annual Report, to provide product specific outcomes or completion of study protocols proposed in the original comparability protocol. Once approved, it will serve as a roadmap for the company and may reduce the overall timelines for the implementation of the change if the FDA agrees to a reduced reporting category. Once submitted and approved, the comparability protocol must be managed and any modifications to the change that may impact the approved conditions of the comparability protocol will need to be submitted to the FDA; if the change to the comparability protocol is significant, it may need to be submitted as another prior-approval supplement or as a CBE-30 supplement as discussed in the FDA’s Draft Guidance.

    Additionally, comparability protocols may also be submitted in relation to the same change that may impact multiple applications, also identified as a grouped supplement. In this case, a lead product (or lead supplement) would be chosen to submit the prior approval comparability protocol prospectively and upon execution of the change, the grouped supplement would be submitted to report the change for multiple applications. A big consideration here is whether the change being contemplated is complex or has the potential to have a significant impact on product quality; if not, the effort and resources needed to submit a proper comparability protocol may ultimately not be worth it. In this case, it is more likely that a comparability protocol will only serve to define the pathway of change and that the FDA may still want to evaluate the change under a prior-approval supplement before implementation. 

    Grouped supplements
    The use of a grouped supplement is a little more simplistic than a comparability protocol and is a good way to consolidate submission of the same change that affects multiple applications. The rough definition of a grouped supplement in FDA’s MAPP 5015.6 Rev.1 is two or more supplements submitted by the same applicant that are reviewed and processed together for an identical change.

    Unfortunately, grouped supplements cannot be submitted by more than one applicant.9 If there are product-specific changes related to the grouped supplement change, these should be submitted under a separate supplement with reference made in the cover letters of both the grouped supplement and the product-specific supplement to link them together. This was recently recommended by the FDA2 and ensures that the FDA is aware of all potentially related changes that could be incorporated into a grouped review. This may be a viable regulatory pathway for implementation of a new line or site change where the initial change has been previously approved under a lead supplement or refurbishing a facility where multiple changes can be consolidated into one supplement and are applicable to multiple applications.

    Lead supplement
    The use of a lead supplement may be something that could be considered for a manufacturing organization where it may be beneficial to submit the change to one application and then leverage the approval of the initial change in either individual or grouped supplements that are the same as that approved for the lead supplement.9,10 This may be useful where the original change is considered prior approval, such as adding an aseptic manufacturing line to an existing facility, and once the facility is reviewed, approved, and inspected (as may be required), additional supplements can be filed as CBE-30 supplements to add the now-approved line.

    The lead supplement approach may also tie into the use of either of the comparability protocol and/or grouped supplement regulatory strategies discussed previously.8 And, if the change arises quickly, and time and resources do not allow for prospective submission of a comparability protocol, then a product-specific prior-approval supplement with a follow up, downgraded grouped supplement—with or without corresponding product specific supplements—all properly referenced and linked—may be the best option. However, as noted in FDA’s Guidance, Prior Approval Supplements Under GDUFA,10 it is recommended that the use of this regulatory pathway is verified as appropriate with the FDA prior to submission.

    It is important to weigh all these considerations carefully including: the complexity of the change, the chances of being able to reduce the reporting category and management of the amount of upfront information needed. This will help give the regulatory staff sufficient time to consider the options before embarking on any particular regulatory pathway to report your manufacturing changes. 

    References
    1. Schwartz, P.;Okubadejo, O; Post Approval Changes: Best Practices and Strategies; Presented at the Associate of Affordable Medicines GRx+Biosims Conference, Bethesda, MD, November 2019.
    2. US Food and Drug Administration. Center for Drug Evaluation and Research. (2004, April). Guidance for Industry, Changes to an Approved NDA or ANDA. Retrieved from https://www.fda.gov/media/71846/download.
    3. US Food and Drug Administration. Center for Drug Evaluation and Research. (2018, September). Draft Guidance for Industry, Postapproval Changes to Drug Substances. Retrieved from https://www.fda.gov/media/115733/download
    4. US Food and Drug Administration. Center for Drug Evaluation and Research. (2014, March). Guidance for Industry, CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports. Retrieved from https://www.fda.gov/media/79182/download
    5. US Food and Drug Administration. Center for Drug Evaluation and Research. (1995, November). Guidance for Industry, Immediate Release Solid Oral Dosage Forms, Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation.  Retrieved from https://www.fda.gov/media/70949/download
    6. US Food and Drug Administration. Center for Drug Evaluation and Research. (1997, September). Guidance for Industry, SUPAC-MR: Modified Release Solid Oral Dosage Forms, Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation.  Retrieved from https://www.fda.gov/media/70956/download
    7. US Food and Drug Administration. Center for Drug Evaluation and Research. (1997, May). Guidance for Industry, Nonsterile Solid Dosage Forms, Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation.  Retrieved from https://www.fda.gov/media/71141/download
    8. US Food and Drug Administration. Center for Drug Evaluation and Research. (2016, April). Draft Guidance for Industry, Comparability Protocols for Human Drugs and Biologics: Chemistry, Manufacturing, and Controls Information.  Retrieved from https://www.fda.gov/media/97148/download
    9.  US Food and Drug Administration. Center for Drug Evaluation and Research, Office of Pharmaceutical Quality. (2016, April). Manual of Policies and Procedures 5015.6 Rev.1, Review of Grouped Product Quality Supplements. Retrieved from https://www.fda.gov/media/72531/download.
    10. US Food and Drug Administration.  Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. (2017, October). ANDA Submissions – Prior Approval Supplements Under GDUFA, Revision 1. Retrieved from https://www.fda.gov/media/89263/download

    Amy Schutte
    Senior Associate, Lachman Consultant Services

    Amy Schutte is a Senior Associate in the Regulatory Practice at Lachman Consultants with nearly 20 years’ experience. She is a pharmaceutical industry professional with specialization in Regulatory Affairs and experience in quality, regulatory compliance, and pharmacovigilance.
    Related Searches
    • modified release
    • generic
    • CMC
    • Testing

    Related FDA Watch

    • Solid Dosage/Creams/Ointments
      Recent Advances in Solid Dispersion Technologies

      Recent Advances in Solid Dispersion Technologies

      Improving the bioavailability and therapeutic efficiency of poorly soluble drugs.
      José L. Toro, Directory, Lachman Consultants 01.27.21

    • The Importance of Hypothesis Testing During Investigations

      The Importance of Hypothesis Testing During Investigations

      Why it is critical to have controls in place during out-of-specification investigations to provide quality assurance.
      Paul Mason, PhD, Lachman Consultants 11.17.20

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      Ensuring Manufacturing Continuity for Essential Medicines

      Ensuring Manufacturing Continuity for Essential Medicines

      Applying the principles of Quality Risk Management to get medicines to market faster.
      John Darby, M.Sc., Senior Director, Lachman Consultant Services, Inc. 09.09.20


    • Biologics, Proteins, Vaccines
      Pharma’s Fight Against the Coronavirus Pandemic

      Pharma’s Fight Against the Coronavirus Pandemic

      A look at the pharma industry’s concerted effort to develop vaccines against the SARS-CoV-2 virus and therapeutics to treat COVID-19.
      Keith O. Webber, Lachman Consultant Services, Inc. 07.15.20

    • Information Technology | Regulatory Affairs
      Data Integrity: Beyond Electronic Records

      Data Integrity: Beyond Electronic Records

      Get your Data Integrity house in order
      Tim Rhines, Ph.D., Director, Lachman Consultant Services, Inc. 05.05.20

    • Regulatory Affairs
      Inquiring Minds Want to Know, Just Ask FDA

      Inquiring Minds Want to Know, Just Ask FDA

      What you need to know prior to submission
      Michelle Ryder, Lachman Consultant 04.01.20


    • Regulatory Affairs
      Inactive Ingredients: Where Guidance Needs to Meet Data

      Inactive Ingredients: Where Guidance Needs to Meet Data

      Looking at FDA’s most recent draft guidance and the struggle with inactive ingredients.
      Sharif Ahmed, Lachman Consultants Services 10.15.19

    • Regulatory Affairs
      Continuous Manufacturing and its Regulatory Challenge

      Continuous Manufacturing and its Regulatory Challenge

      ...
      José L. Toro, PhD, Lachman Consultants 09.16.19

    • QA/QC | Validation
      Considerations for Analytical Method Validation Lifecycle Controls

      Considerations for Analytical Method Validation Lifecycle Controls

      ICH is set to implement new regulatory guidance dedicated to analytical method development
      Paul Mason, PhD, Lachman Consultants 07.15.19


    • Regulatory Affairs
      Effective Post Market Supplier Strategy for Combination Products

      Effective Post Market Supplier Strategy for Combination Products

      Combinations are typically designed, developed and maintained under a robust contract manufacturing process
      Lori-Ann Woodard CBA, CQE, CSQE, Lachman Consultant Services 06.13.19

    • QA/QC
      Nitrosamines

      Nitrosamines

      How to address these unwelcome guests in the pharmaceutical world
      Aloka Srinivasan, Ph.D., Lachman Consultant Services 05.07.19

    • Regulatory Affairs
      KASA to Support Generic Drug Review

      KASA to Support Generic Drug Review

      FDA expects the new system to advance OPQ’s focus on pharmaceutical quality, the foundation for ensuring the safety and efficacy of drugs.
      Sharif Ahmed, Lachman Consultant Services 04.05.19


    • Regulatory Affairs
      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      A look at how the FDA will administer the transition of NDAs to BLAs
      Keith Webber, Ph.D., Lachman Consultant Services 03.06.19

    • Regulatory Affairs
      Reporting CPPs to FDA

      Reporting CPPs to FDA

      Importance of identifying critical process parameters in original submissions to FDA.
      Aloka Srinivasan, Ph.D. Lachman, Consultant Services 10.10.18

    • Regulatory Affairs
      FDA and Field Alert Reports

      FDA and Field Alert Reports

      Analysis of “Field Alert Report Submission Questions and Answers Guidance for Industry”
      Constance Richard-Math, Lachman Consultants 09.11.18

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    • Pfizer Partners With Medicines Manufacturing Innovation Center
    • ICON Acquires Medpass
    Breaking News
    • Spark Therapeutics Appoints CTO
    • Cryoport Launches ESG Program
    • U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    • Thermo Fisher Scientific Completes Mesa Biotech Acquisition
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    ACI Urges Senate to Approve Regan as EPA Administrator
    Estée Lauder Signs Actress Ana de Armas
    GUM Recalls Oral Spray
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login